Benzinga | Sep 30, 2021 01:47PM EDT

Insulet's Insulin Delivery System Shows Durable Glycemic Control With One Year of Use

* Insulet Corporation (NASDAQ:PODD) presented data from the pivotal trial extension phase of the Omnipod 5 Automated Insulin Delivery System.

* Omnipod 5 is a tubeless, wearable system that continuously adapts insulin delivery based on glucose levels and trends.

* Data showed Omnipod 5 significantly improved time in range and reduced HbA1c patients aged 6-70 years with type 1 diabetes over a period of 12 months.

* The data was presented at EASD 2021, the annual meeting of the European Association for the Study of Diabetes.

* After three months of system use, adults and adolescents had a decrease in HbA1c from 7.2% to 6.8%.

* This decrease was maintained after a total of 12 months of use, with mean HbA1c remaining at 6.8%.

* The Omnipod 5 System received breakthrough device designation from the FDA and is currently under premarket review.

* Insulet expects to launch Omnipod 5 in limited release in the U.S. late in Q4 of 2021.

* Insulet also presented new clinical outcomes data for people with type 1 diabetes using the Omnipod DASH System for 90 days and positive self-management behaviors.

* Related: FDA Clears Use Of Eli Lilly's Insulin With Insulet's Infusion Pumps.

* Price Action: PODD stock is up 1.42% at $282.93 during the market session on the last check Thursday.